Lily Li, Ph.D.

Lily Li is a Director at Northpond Ventures where she focuses on life science tools and diagnostics. Lily is a board director at 1859, Ansa Biotechnologies, SpeeDx, and Vestaron, and holds board observer roles at ChromaCode, Delfi Diagnostics, Emulate, and Encodia. She was a board director at Personal Genome Diagnostics (PGDx) which was acquired by LabCorp. Previously, Lily was an Associate Director of corporate and business development at Illumina (NASDAQ: ILMN), where she structured and led strategic partnerships to support company growth across clinical markets. Prior to Illumina, Lily led strategic marketing and business development at NanoString Technologies, Inc. (NASDAQ: NSTG). Lily was also a management consultant in the life sciences practice at L.E.K. Consulting, where she served as a strategic advisor to a broad range of corporate clients and life science investors. Lily received her Ph.D. in molecular and systems pharmacology from Emory University. She also holds a B.S. in biology from Tsinghua University.